柴芍三白汤治疗反流性食管炎肝胃不和证的临床疗效观察

发布时间：2018-02-03 13:05

本文关键词： 柴芍三白汤反流性食管炎肝胃不和证临床疗效观察　出处：《湖南中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的:观察柴芍三白汤治疗反流性食管炎肝胃不和证患者临床疗效及安全性。方法:选取2015年2月至2016年1月湖南中医药大学第一附属医院消化内科门诊招募,符合反流性食管炎肝胃不和证诊断标准的患者60例,分为治疗组30例,对照组30例,治疗组给予柴芍三白汤,对照组给予雷贝拉唑联合莫沙必利,两组疗程均为8周,治疗结束后对疾病疗效、中医证候总积分变化、胃镜下食管黏膜分级计分、不良反应等方面进行比较统计分析。结果:(1)柴芍三白汤组临床疗效总有效率90%;雷贝拉唑联合莫沙比利组总有效率76.67%,两组总有效率比较差异有统计学意义(p0.05)。(2)中医证候总积分变化,两组治疗前与治疗后比较差异有统计学意义(p0.05),治疗后中药组与西药组比较差异具有统计学意义(P0.05)。在改善主症反酸、烧心方面,中药组和西药组比较,差异无统计学意义(p0.05),在改善主症胸骨后疼痛方面,两组比较差异有统计学意义(p0.05),中药组疗效优于西药组;在改善次症纳差方面,两组比较无统计学意义(p0.05),在改善次症嗳气呃逆、喜太息、脘腹胀满或胀痛方面,两组比较差异有统计学意义(p0.05),中药组疗效优于西药组。(3)胃镜下食管黏膜分级记分比较,中药组和西药组治疗后比较差异具有显著统计学意义(p0.01)。(4)不良反应观察,中药组治疗期间未出现明显不良反应及毒副作用,西药组出现恶心2例,未经处理,自然消失。结论:柴芍三白汤治疗反流性食管炎肝胃不和证患者疗效肯定,能有效缓解临床症状,改善胃镜下食管黏膜病变情况,且安全性良好无副作用,值得临床推广。
[Abstract]:Objective: to observe the clinical efficacy and safety of Chaixiaoshanbai decoction in the treatment of reflux esophagitis with liver-stomach disharmony syndrome. From February 2015 to January 2016, the first affiliated Hospital of Hunan University of traditional Chinese Medicine was recruited from the Department of Digestive Medicine. Sixty patients with reflux esophagitis were divided into treatment group (n = 30) and control group (n = 30). The course of treatment in both groups was 8 weeks. After the treatment, the curative effect, the total integral change of TCM syndromes and the score of esophageal mucosal grading under gastroscopy were observed. The adverse reactions were compared and analyzed. Results the total effective rate was 90 in the Chaixiaoshanbai decoction group. The total effective rate of rabeprazole combined with mosapride group was 76.67. The difference of total effective rate between the two groups was statistically significant. The difference between the two groups before and after treatment was statistically significant (P 0.05), and the difference between the Chinese medicine group and the western medicine group was statistically significant (P 0.05). There was no significant difference between the Chinese medicine group and the western medicine group, but there was no significant difference between the two groups in improving the pain after sternum of the main symptom. The curative effect of the traditional Chinese medicine group was better than that of the western medicine group. There was no significant difference between the two groups in improving the anorexia of the secondary symptoms. The two groups had no statistical significance in improving the belching hiccup in the secondary syndrome, and in the improvement of belching hiccup, too much information, abdominal distension or distending pain. The difference between the two groups was statistically significant (P 0.05). The curative effect of the traditional Chinese medicine group was better than that of the western medicine group. 3) the score of esophageal mucosal grading under gastroscopy was better than that in the traditional Chinese medicine group. There was significant difference between the Chinese medicine group and the western medicine group after treatment. There was a significant difference between the two groups in the observation of adverse reactions. There were no obvious adverse reactions and side effects during the treatment period in the Chinese medicine group. Western medicine group of 2 cases of nausea, untreated, natural disappearance. Conclusion: Chaixiaoshanbai decoction treatment of reflux esophagitis liver and stomach disharmony syndrome, the curative effect is certain, can effectively alleviate the clinical symptoms. To improve the esophageal mucosal lesion under gastroscopy, and the safety is good, no side effect, worthy of clinical promotion.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】